Distance Traveled and Cross-State Commuting to Opioid Treatment Programs in the United States
2011

Distance Traveled to Opioid Treatment Programs in the U.S.

Sample size: 23141 publication Evidence: moderate

Author Information

Author(s): Andrew Rosenblum, Charles M. Cleland, Chunki Fong, Deborah J. Kayman, Barbara Tempalski, Mark Parrino

Primary Institution: National Development and Research Institutes, Inc. (NDRI)

Hypothesis

Travel distance to opioid treatment programs is negatively correlated with urbanicity.

Conclusion

A significant number of patients travel considerable distances to access opioid treatment programs, with various factors influencing their commuting patterns.

Supporting Evidence

  • 60% of patients traveled less than 10 miles to their OTP.
  • 8% of patients traveled across state lines to attend an OTP.
  • Patients in the Southeast and Midwest traveled greater distances than those in the Northeast and West.
  • Patients using prescription opioids traveled further than those using heroin.

Takeaway

Many people who need help for opioid addiction have to travel far to get it, and some even go to another state for treatment.

Methodology

Patients completed an anonymous one-page survey, and a linear mixed model analysis was used to predict distance traveled to the treatment program.

Potential Biases

The sample may not be representative of all opioid treatment program enrollees due to selection bias in OTPs chosen for the study.

Limitations

Travel distances were estimated based on ZIP code centroids, which may not accurately reflect actual travel times or distances.

Participant Demographics

Patients ranged in age from 18 to 81 years, with a median age of 32; most were male and non-Hispanic white.

Statistical Information

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/2011/948789

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication